Low-Dose Alteplase No Better for Acute Ischemic Stroke

Share this content:
Low-Dose Alteplase No Better for Acute Ischemic Stroke
Low-Dose Alteplase No Better for Acute Ischemic Stroke

MONDAY, Oct. 2, 2017 (HealthDay News) -- For key demographic subgroups of patients with acute ischemic stroke (AIS), low-dose alteplase does not differ from standard-dose alteplase in terms of treatment effects on death or disability, according to a study published online Oct. 2 in JAMA Neurology.

Xia Wang, Ph.D., from the University of New South Wales in Australia, and colleagues conducted a prespecified secondary analysis of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study clinical trial of low- versus standard-dose intravenous alteplase for patients with AIS. A total of 3,310 patients with a clinical diagnosis of AIS, confirmed by brain imaging, were included in the alteplase-dose arms; participants were randomized to receive low- or standard-dose alteplase. A total of 3,297 patients were included in the analysis.

The researchers found that there were no significant differences between low- and standard-dose alteplase in the treatment effects for poor outcomes (death or disability) by age, ethnicity, or severity (all P > 0.37 for interaction). The treatment effects of low- versus standard-dose alteplase on functional outcome was consistent for Asians and non-Asians (P = 0.32 for interaction). The reductions in rates of symptomatic intracerebral hemorrhage were generally consistent with low-dose alteplase, although the reduction was not significant by age, ethnicity, or severity.

"Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

Study Finds 31 Percent Use No Opioids After Surgery

Study Finds 31 Percent Use No Opioids After ...

At discharge, 92.2 percent of patients received an opioid prescription; nearly 63 percent unused

PAs May Have Lower Diagnostic Accuracy for Melanoma

PAs May Have Lower Diagnostic Accuracy for Melanoma

PAs diagnose fewer melanomas in situ, perform more skin biopsies per case of skin cancer diagnosed

AAN: Neuromodulation Therapy Gives Relief From Hand Tremor

AAN: Neuromodulation Therapy Gives Relief From Hand Tremor

Non-invasive neuromodulation therapy using a custom stimulation pattern safe for essential tremor

is free, fast, and customized just for you!

Already a member?

Sign In Now »